Chronic Lymphocytic Leukemia: Autoimmune Presentations in A tertiary Care Hospital of Lahore

Arsala Rashid¹, Mukarrama Rashid ², Nabila Aslam³, Huma Sheikh ⁴, Ambreen Kashif⁵, Ayesha Khanum⁶

¹,⁴ Senior Demonstrator, King Edward Medical University Lahore, ² House Officer, Sheikh Zayed Hospital, Lahore
³Consultant Mughal Diagnostic Laboratory, ⁴Senior Demonstrator Fatima Memorial Hospital Lahore
⁵Medical officer children Hospital Lahore

ABSTRACT

Objective: To determine the frequency of presenting features and complications in chronic lymphocytic leukemia.

Methodology: This descriptive study was conducted at the Hematology department, King Edward Medical University and affiliated hospitals, from 20 July to 20 December 2017. For every patient, a through clinical and dermatological examination, abdominal ultrasound and bone marrow examination was done. A fresh blood sample for CBC, immune profile, and serum testing was collected by a syringe using aseptic technique. A complete blood count was carried out and chemical examination was done. Reticulocyte count was performed and direct antiglobulin test using coomb's reagent was done. Every patient was evaluated for the criteria of SLE and was categorized accordingly.

Results: Out of the 150 patients enrolled in the study, 122(81.3%) were male and 28(18.7%) were female. The mean age was 65.8 ± 1.33 years with the majority of patients falling in the group of 71- 80 years. Out of 150 patients, 40 (26.7%) had Coombs test positive. Most of the patients who had Coombs positive were in stage 4 CLL. The patients who presented with complications such as paraneoplastic pemphigus were 1 out of the 150 patients. Splenomegaly was found in 87.3 % of all CLL patients where 13.33% presented with massive splenomegaly. Angioedema was found in 2 out of 150 patients. No case of SLE, Sjogren’s syndrome, Churg strauss Syndrome, Vasculitis or Richters Tranformation was found.

Conclusion: Detection of complications in a significant number of CLL patients is related to disease progression and overall survival. The treatment modalities are different in different causes of anaemia and complications due to CLL. It will help the clinicians in modifying the treatment and decreasing the misery of patients due to co morbidities.

Keywords: CLL, Autoimmune anaemia, complications of CLL.

Introduction

Chronic lymphocytic leukaemia (CLL) is characterized by proliferation, accumulation, and sustained increase of morphologically mature but functionally incompetent lymphocytes. Autoimmune phenomena are a well-known complication of lymphoproliferative diseases. Autoimmune Haemolytic Anaemia is the most frequent autoimmune disorder associated with CLL although patients may present with widespread immune complications.
laboratory features. The initial diagnostic investigations are morphology and immunophenotype. These tests should be complemented with molecular genetics and/or histology to exclude other B-cell disorders of small lymphocytes. The clinical course of patients with B-cell chronic lymphocytic leukemia (CLL) is often made complicated by autoimmune phenomena that mainly target blood cells. Complications can occur in up to a quarter of all patients during the course of the illness. It is not true to say that autoimmunity is confined to the formed elements of the blood since conditions such as paraneoplastic pemphigus and acquired angioedema do occur in CLL, but nonhematologic autoimmunity is very rare indeed(2). Autoimmunity is usually caused by loss of self-tolerance resulting in a pathologic immune response to autologous blood cells. Most cases of AIHA and ITP are caused by high-affinity polyclonal IgG directed against red blood cells (RBCs) or platelet antigens.(3) (4)Autoantibodies specific for RBCs are detectable by the direct antiglobulin test in up to 20% of patients with advanced CLL but cause AIHA in only a minority of these patients.

The diagnosis of CLL requires the presence of 5 × 10^9/L B lymphocytes in the peripheral blood, sustained for at least 3 months.CLL cells coexpress the surface antigen CD5 together with the B-cell antigens CD19, CD20, and CD23.

Each clone of leukemia cells is restricted to expression of either kappa or lambda immunoglobulin light chains. The staging methods of chronic lymphocytic leukaemia that are currently in use throughout the world are the Rai and the Binet systems. In the three-stage Rai system low risk encompasses Rai stage 0, with the clinical features of lymphocytosis in blood and bone marrow only. Intermediate risk encompasses stage I, with lymphocytosis and enlarged nodes, and stage IV with lymphocytosis plus splenomegaly and or hepatomegaly (nodes positive or negative). Infections are the major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). Predisposition to infection in CLL is mediated through various abnormalities, including both the immune defects inherent in the primary disease (impairment in humoral and cellular immunity) and in the further immunosuppression related to the management of CLL. Hypogammaglobulinemia is probably the most important immune defect in terms of the risk of severe bacterial infections, its frequency and severity progressing with the duration of the disease.

Methodology

This descriptive study was conducted in the Hematology Department of King Edward Medical University and affiliated hospitals during a period six months after the approval of the synopsis, from 20 July to 20 December 2017. The sampling technique used was non-probability purposive sampling. Sample size of 150 patients was estimated by using a 95% confidence level. 7% margin of error, with expected frequency of complications in patients of chronic lymphocytic leukaemias was taken as 19.4%. Newly diagnosed cases and cold cases of chronic lymphocytic leukaemia that had not taken any treatment with age up to 85 years were included. Patients on treatment or having been treated for chronic lymphocytic leukaemia were not included. Patients who had received transfusion within last three months and known cases of autoimmune disorders like systemic lupus erythematosus, lupus nephritis, pemphigus vulgaris and giant cell arthritis were excluded. Patients taking drugs known to cause haemolytic anaemia like quinidine, penicillin, and methylprednisolone and on steroid therapy were not included.

For every patient, a detailed history, clinical examination, skin biopsy, and CBC was run on a fresh 3 ml blood sample containing EDTA using Automated Haematology Analyzer (Sysmex KX-21). Reticulocyte count was done by supravital staining. Direct antiglobulin test using antihuman globulin, Bilirubin and Lactate dehydrogenase levels were measured using XN 1000.Data was entered and analysed on SPSS version 20 computer software and program for data analysis. Quantitative variables including age of the patient, complete blood counts and bilirubin levels, reticulocyte count and lactate dehydrogenase levels were presented as mean ± standard deviation. Qualitative variables including autoimmune haemolytic anaemia, gender, AHA, massive splenomegaly were presented as frequency/percentages. Data was entered and analysed on SPSS version 20, computer software and program for data analysis. Quantitative variables including age of the patient, complete blood counts and bilirubin levels, reticulocyte count and lactate dehydrogenase levels were presented as mean ± standard deviation. Qualitative variables including autoimmune haemolytic anaemia, gender, AHA, massive splenomegaly were presented as frequency/percentages. Data for age, gender and duration of CLL was stratified. Post stratification chi square test was applied and P value ≤ 0.05 was considered as significant.
Results

In our study, 150 patients of CLL were enrolled. Enrolled patients age ranged from 40-85 years with mean age of 65.8 ±1.5 years with maximum number of 45 (30%) patients falling in the group of 71-80 years.(Figure 2) Maximum number of patients 50 (33.3%) fell in stage II (according to Binet classification) followed by 45 (30%) in stage III, 42 patients (28%) in stage IV, 12 (8%) in stage I and only 1 patient (0.675) in stage 0.

Figure 1. CCL patients presenting with different stages of diseases

Figure 2. Age distribution group wise in patients of CLL

The mean haemoglobin of all CLL patients was 9.8 g/dl ± 2.62. 15 % of patients were suffering from anemia. Mean Bilirubin levels in CLL patients were 1.3 ± 0.5 mg/dL (Figure 4) and a much higher mean of 3.5 ± 1.45 mg/dL in patients who had haemolytic anemia. The patients who presented with complications such as paraneoplastic pemphigus were 1 out of 150 patients. Splenomegaly was found in 87.3 % of all CLL patients with 13.33% presenting with massive splenomegaly.(Figure 3) Angioedema was found in 2 out of 150 patients. No case of SLE, Sjogren’s syndrome Churg strauss Syndrome, Vasculitis or Richters Trasnsformation was found.

Figure 3. Autoimmune Complication of CLL

Figure 4. Bilirubin level in patients of CLL

Discussion

In this study, we included 150 patients with a diagnosis of CLL. This was a prospective cross sectional survey which was conducted in a well-equipped tertiary care unit. The mean age of the patients in our study was 65.8 ± 1.5 years with the maximum number of patients falling in the group of 71-80 years. While in another local study by Ehsan AY et al,6,7 the mean age of cohort was 62.84 years. The majority of the patients in our study were male, i.e. 81.33% with a male to female ratio of 4.3:1.

Oppezo P et al8 conducted a study showing that 63% of the population under study was male. Another study conducted in the Hospital Clinic of Barcelona, which divided their patients into two groups from 1980-1994 and from 1995-2008 showed Median age of patients presenting with clinical features was higher in patients diagnosed between 1980 and 1994 than in those seen from 1995 to 2004 (68 vs 64 years; P = .005). The distribution by age group revealed a trend toward younger ages at diagnosis,
with a significant increase in the proportion of patients younger than 70 years old (55.9% vs. 63%; P = .039). There was also increased prevalence of men in both groups (54.3% vs 58.4%; P = NS). In our study, the maximum number of patients 50 (33.3%) fell in stage II (according to Binet classification), followed by 45 (30%) in stage III, 42 patients (28%) in stage IV, 12 (8%) in stage I and only 1 patient (0.675) in stage 0. In the study mentioned above conducted in Barcelona, majority of patients were from Binet stage A (75.6%) and minimum were from stage C (8.8%), and 15.6% from stage B. 9,10

Our results also showed that the mean haemoglobin of all CLL patients was 9.8 g/dl ± 2.62. Around 15 % of patients were suffering from anaemia. Another study similar to ours conducted from November 2002 to December 2008, in which 112 young patients (<65 years) diagnosed with CLL were included. There were 62 males and 50 females, with a median age of 52 years (range 29–68). Eighty-one percent were in Binet stage A, 19% were in stages B/C. Rai stage 0 was recorded in 61% of patients, I/II in 33.5%, III/IV in 5.5%. Their median heamoglobin was 14 in all 112 cases and Hb 14.2 in stage A patients that was 90. The University of California, San Francisco results showed that patients with splenomegaly was much common as the acute leukemias for splenomegaly and six times more common for massive splenomegaly. (23%) Another study conducted in Northern Nigeria, 4 out of 30 patients with splenomegaly, had Chronic Lymphocytic Leukemia. 13,14 Our study also showed that 2 out of 150 patients had acquired angioedema. There is a well-known link between acquired angioedema and lymphoplasmacytic disorders. 15,16 In a study that studied this relationship, they noted that while reviewing 32 patients with Acquired angioedema, nine (28%) had lymph proliferative disease. 17,18,19

Conclusion

Detection of complications in a significant number of CLL patients is related to disease progression and overall survival. The treatment modalities are different for different causes of anaemia and complications due to CLL. This will help clinicians modify the treatment and decrease the misery of patients due to co morbidities.

References

1. Matutes E, Wotherspoon A, Catovsky D. Differential diagnosis in chronic lymphocytic leukaemia. Best Practice & Research Clinical Haematology. 2007 Sep;20(3):367-84. https://doi.org/10.1016/j.beha.2007.03.001

2. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Seminars in oncology 2006 Apr 1 (Vol. 33, No. 2, pp. 230-239). WB Saunders. https://doi.org/10.1053/j.seminoncol.2006.01.011

3. Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfusion medicine reviews. 2010 Jul 1;24(3):195-210. https://doi.org/10.1016/j.vhr.2010.03.002

4. Naysmith JD, ORTEGA-PIERRES MG, Elson CJ. Rat erythrocyte-induced anti-erythrocyte autoantibody production and control in normal mice. Immunological reviews. 1981 Apr;55(1):55-87. https://doi.org/10.1111/j.1600-065x.1981.tb00339.x

5. Robak T, Blasińska-Morawiec M, Krykowski E, Hellmann A, Konopka L. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). European journal of haematology. 1997 Feb;58(2):109-13. https://doi.org/10.1111/j.1600-0609.1997.tb00933.x

6. Ehsan A, Lone A, Khan MA. Autoimmune complications in chronic lymphocytic leukemia: a single center experience. Biomedica. 2013;29:37-41.

7. Haider MS, Khan SA, Nasiruddin SS. Autoimmune cytopenias in chronic lymphocytic leukemia. Pakistan Journal of Medical Sciences. 2019 Sep;35(5):1334. https://doi.org/10.12669/pjms.35.5.369

8. Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, Kimura EY, Bechet S, Dumas G, Brissard M, Merle-Béral H. The LAP/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. blood. 2005 Jul 15;106(2):650-7. https://doi.org/10.1182/blood-2004-08-3344

9. Abrisqueta P, Pereira A, Rozman C, Aymerich M, Giné E, Moreno C, Muntanolla A, Rozman M, Villamor N, Hodgson K, Campo E. Improving survival in patients with chronic lymphocytic leukaemia (1980-2008): the Hospital Clinic of
10. Montserrat E. Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. InLymphoma 2013 (pp. 65-82). Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-408-1_4

11. Del Giudice I, Mauro FR, De Propis MS, Santangelo S, Marinelli M, Peragine N, Di Maio V, et al. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. haematologica. 2011 Apr;96(4):626. https://doi.org/10.3324/haematol.2010.028779

12. Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, Girelli G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood, The Journal of the American Society of Hematology. 2000 May 1;95(9):2786-92. https://doi.org/10.1182/blood.V95.9.2786.009k30_2786_2792

13. O’Reilly RA. Splenomegaly in 2,505 patients at a large university medical center from 1913 to 1995. 1963 to 1995: 449 patients. Western journal of medicine. 1998 Aug;169(2):88.

14. Stoelting A, Esperti S, Balanchivadze N, Piacentino V, Mangano A. Sarcoidosis presenting as massive splenomegaly and severe epistaxis, case report. Annals of Medicine and Surgery. 2020 Jun 1;54:6-9. https://doi.org/10.1016/j.amsu.2020.03.007

15. Bryceson AD, Fleming AF, Edington GM. Splenomegaly in northern Nigeria. Acta Tropic. 1976 Jan 1;33(3):185-214.

16. Mohyuddin GR, Rabinowitz I. A patient with chronic lymphocytic leukemia and acquired angioedema: correlation of clinical and biochemical response to CLL therapy. ecancermedicalscience. 2013,7.

17. Diehl LF, Karnell LH, Menck HR. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1999 Dec 15;86(12):2684-92. https://doi.org/10.1002/(SICI)1097-0142(19991215)86:12<2684::AID-CNCR13>3.0.CO;2-V

18. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood. 2004 Sep 15;104(6):1850-4. https://doi.org/10.1182/blood-2004-01-0341

19. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood. 2004 Sep 15;104(6):1850-4. https://doi.org/10.1182/blood-2004-01-0341